Faculty

Institution

Unit

Venue

Melody A. Cobleigh

Rush University

Affiliations

Division Of Hematology/Oncology/Cell Therapy

News & Events

Rush University

Melody A. Cobleigh is a High Senior Professor at Rush University. Her research focuses on breast cancer therapeutics, including HER2-targeted agents, antibody-drug conjugates, and immunotherapy combinations for metastatic disease. She has led trials on zanidatamab with chemotherapy, sacituzumab-govitecan in triple-negative breast cancer, and neratinib in HER2-mutated tumors. Her work also explores mutations such as PIK3R1 activating targetable pathways. She has contributed to the Phase III TULIP trial of trastuzumab duocarmazine and investigates tumor microenvironment reprogramming with eganelisib. Her research advances precision oncology and treatment outcomes for advanced breast cancer.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Melody A. Cobleigh

Rush University

You can click a keyword to filter the displayed items

oncology breast cancer breast oncology cancer treatment cancer care pharmacology radiation oncology cancer research metastasis medicinal research medicine molecular cancer clinical research oncogenes cancer biology metastatic breast cancer pharmacotherapy cancer management surgical oncology tumor biology anti-cancer agents cancer imaging clinical trials cancer cells biostatistics gynecologic oncology therapeutic targets tumor targeting cancer genetics cancer discovery endocrine-related cancers cancer registration cellular therapy vascular biology therapeutic efficacy leukemia radiation therapy drug targeting breast imaging hormonal receptor thoracic oncology breast surgery clinical radiation oncology phase ii study phase ii trial breast cancer survivors clinical investigation pharmacological research lymphoid neoplasia field trial cancer screening endocrine oncology drug trials treatment options clinical evidence medical genetics gastrointestinal oncology randomized controlled trials receptor tyrosine kinases patient characteristics novel combination treatment development prospective cohort studies cohort studies chemoprevention strategies patient-reported outcomes aromatase inhibitors postmenopausal women advanced breast cancer phase iii study sunitinib malate first-line therapy situ hybridization progression-free survival overall survival t-cell subsets

Notable Scholarly Works

Notable Federal Grants

Collaborators

303Mo Zanidatamab (Zani) + Chemotherapy (Chemo) for Patients (Pts) With Her2-Expressing Metastatic Breast Cancer (Mbc): Final Results of a Phase I Trial. ESMO Open (2025)

breast oncologymetastasisradiation oncologyanti-cancer agentsmolecular cancerfinal resultsmedicinepharmacologypharmacotherapycancer treatmentcancer careoncologybreast cancer

Abstract 5987: Mutations in Pik3R1 Activate Multiple Targetable Pathways in Triple-Negative Breast Cancer. Cancer Research (2025)

oncogenesreceptor tyrosine kinasescancer biologycell signalingcell biologyabstract 5987molecular cancermolecular diagnosticsmultiple targetable pathwaysmolecular biologytriple-negative breast cancercancer cellscancer geneticsbreast cancer

Abstract P1-12-29: Extreme Response to Sacituzumab-Govitecan in a Patient With Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research (2025)

breast oncologyoncogenesmetastasispathologyradiation oncologyabstract p1-12-29anti-cancer agentsmolecular cancercancer cellsextreme responsecancer treatmentcancer careoncologybreast cancer

A Prospective Study of Serum Folate Levels in Patients With Solid Tumors Treated With Olaparib. The Oncologist (2025)

serum folate levelspathologyradiation oncologyclinical biochemistrymalignant diseasesurgical oncologycancer researchsolid tumorscancer treatmentprospective studycancer lettercancer careoncology

The Phase II Muther Study of Neratinib Alone and in Combination With Fulvestrant in Her2-Mutated, Non-Amplified Metastatic Breast Cancerneratinib and Fulvestrant in Her2-Mutated Breast Cancer. UNC Libraries (2025)

breast oncologyoncogenesmetastasispathologyradiation oncologycell biologymolecular cancerneratinib aloneher2-mutated breast cancercancer cellscancer treatmentoncologybreast cancer

CORRECTION: Soluble Urokinase Plasminogen Activator Receptor and Cardiotoxicity in Doxorubicin‑Treated Breast Cancer Patients: A Prospective Exploratory Study. Cardio-Oncology (2024)

breast oncologycardiovascular toxicityprospective exploratory studyanti-cancer agentsmedicinepharmacologypharmacotherapycancer treatmentcancer careoncologybreast cancer

Eganelisib Combined With Immune Checkpoint Inhibitor Therapy and Chemotherapy in Frontline Metastatic Triple-Negative Breast Cancer Triggers Macrophage Reprogramming, Immune Activation and Extracellular Matrix Reorganization in the Tumor Microenvironment. Journal for ImmunoTherapy of Cancer (2024)

Brenda C O'ConnellCharley HubbardNora ZizlspergerDonna FitzgeraldJeffrey L KutokJudith VarnerRobert IlariaMelody A CobleighDejan JuricKate H R TkaczukAnthony EliasArielle LeeShaker DakhilErika HamiltonHatem SolimanStephane Peluso

oncogenesmetastasispathologyextracellular matrix reorganizationcancer biologycancer immunotherapyimmunopathologyimmunologyimmune activationimmunotherapycancer immunosurveillancesystems biologycancer cellscancer treatmentimmune checkpoint inhibitorstumor microenvironmentbreast cancer

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (Tulip). Journal of Clinical Oncology (2024)

Nicholas TurnerCristina SauraPhilippe AftimosEvelyn van den TweelMayke OesterholtNorbert KoperMarco ColleoniEmilie KaczmarekKevin PunieXinni SongAnne ArmstrongGiulia BianchiAgostina StradellaSylvain LadoireJoline Si Jing LimNathalie Quenel-TueuxTira J. TanSantiago Escrivá-de-RomaníJoyce O'ShaughnessyEvelien KuipElisabeth G.E. de VriesWillemien Menke-van der Houven van OordtPhilippe AftimosKonstantinos PapadimitriouHannelore DenysKevin PunieGuy JerusalemMarleen BormsFrançois DuhouxNicholas TurnerIain MacphersonAnne ArmstrongNicola LevittCarlo PalmieriAnnabel BorleyTimothy CrookEstela Vega AlonsoSerafin MoralesSantiago Escriva de Romani MuñozAgostina StradellaYolanda Jerez GilarranzAntonio AntonJose Juan PonceBarbara AdamoJavier Cortes CastanMaria MartinezThierry PetitEmilie KaczmarekSylvain LadoireNathalie Quenel TueuxLuis TeixeiraJean Christophe TherySophie Abadie-LacourtoisieAlain LortholaryElisabeth LuporsiHubert OrfeuvreNathalie BonninGiampaolo BianchiniFederico PiacentiniFrancesco CognettiPaolo MarchettiEvaristo MaielloMarina CazzanigaValentina GuarneriMarco ColleoniLaura DoniRoberto BordonaroClaudio ZamagniGiulia BianchiLaura BiganzoliMichael ThirlwellXinni SongAnil JoySara TaylorTeresa HelstenMadhu ChaudhryHaythem AliShaker DakhilRex MowatAdam BrufskyMelody CobleighManuel ModianoMichelina CairoMichael MeshadMichael A. DansoJay AndersenAllyson HarroffRami OweraAnne FavretJoyce O'ShaughnessyTimothy PluardPaula RosenblattSharad JainJeanette Dupont JensenNina JeppesenKim WedervangPer EdlundHenrik LindmanRenske AltenaLeif Klint

breast oncologygynecologic oncologyimmunologysurgical oncologydermatologychemoprevention strategiescancer discoverypharmacologymetastatic breast cancerbreast cancercancer researchoncogenestrastuzumab duocarmazinemedicinal researchfield trialmetastasistumor targetingoncologyiii trialclinical researchtherapeutic efficacy

Abstract 2248: Activity of Targeted Agents in Pik3R1 Mutated Patient-Derived Xenografts. Cancer Research (2023)

oncogenestargeted agentstumor biologyanti-cancer agentsabstract 2248cell biologycancer growthpharmacologytherapeutic targetscancer cellspatient-derived xenografts

Comparative Genomic Analysis of Pik3R1-Mutated and Wild-Type Breast Cancers. Breast Cancer Research and Treatment (2023)

breast oncologyoncogenescomparative genomic analysiscell biologymolecular diagnosticsgeneticscancer geneticscancer genomicsbreast cancer

1
2
3
4
5
16
10 / page

Melody A. Cobleigh

Rush University

Affiliations

Division Of Hematology/Oncology/Cell Therapy

News & Events

Rush University

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Melody A. Cobleigh

Rush University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

303Mo Zanidatamab (Zani) + Chemotherapy (Chemo) for Patients (Pts) With Her2-Expressing Metastatic Breast Cancer (Mbc): Final Results of a Phase I Trial. ESMO Open (2025)

breast oncologymetastasisradiation oncologyanti-cancer agentsmolecular cancerfinal resultsmedicinepharmacologypharmacotherapycancer treatmentcancer careoncologybreast cancer

Abstract 5987: Mutations in Pik3R1 Activate Multiple Targetable Pathways in Triple-Negative Breast Cancer. Cancer Research (2025)

Abstract P1-12-29: Extreme Response to Sacituzumab-Govitecan in a Patient With Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research (2025)

breast oncologyoncogenesmetastasispathologyradiation oncologyabstract p1-12-29anti-cancer agentsmolecular cancercancer cellsextreme responsecancer treatmentcancer careoncologybreast cancer

A Prospective Study of Serum Folate Levels in Patients With Solid Tumors Treated With Olaparib. The Oncologist (2025)

serum folate levelspathologyradiation oncologyclinical biochemistrymalignant diseasesurgical oncologycancer researchsolid tumorscancer treatmentprospective studycancer lettercancer careoncology

breast oncologyoncogenesmetastasispathologyradiation oncologycell biologymolecular cancerneratinib aloneher2-mutated breast cancercancer cellscancer treatmentoncologybreast cancer

CORRECTION: Soluble Urokinase Plasminogen Activator Receptor and Cardiotoxicity in Doxorubicin‑Treated Breast Cancer Patients: A Prospective Exploratory Study. Cardio-Oncology (2024)

breast oncologycardiovascular toxicityprospective exploratory studyanti-cancer agentsmedicinepharmacologypharmacotherapycancer treatmentcancer careoncologybreast cancer

Abstract 2248: Activity of Targeted Agents in Pik3R1 Mutated Patient-Derived Xenografts. Cancer Research (2023)

oncogenestargeted agentstumor biologyanti-cancer agentsabstract 2248cell biologycancer growthpharmacologytherapeutic targetscancer cellspatient-derived xenografts

Comparative Genomic Analysis of Pik3R1-Mutated and Wild-Type Breast Cancers. Breast Cancer Research and Treatment (2023)

breast oncologyoncogenescomparative genomic analysiscell biologymolecular diagnosticsgeneticscancer geneticscancer genomicsbreast cancer

1
2
3
4
5
16
10 / page